Full-Time
Azure Data Engineer
Posted on 11/1/2025
Cencora
10,001+ employees
Global pharmaceutical distribution and services provider
No salary listed
Pune, Maharashtra, India
In Person
 Data & Analytics (2) |
|---|
| , |
- A Bachelor's Degree in Computer Science, Information Systems, or a related field
- 5+ years of experience in cloud based data related role
- MS Azure certification(s) is an asset
- Excellent communication skills, both written and verbal
- Strong analytical and problem-solving skills
- Meticulous attention to detail
- Azure SQL / MS SQL Server
- Azure Analysis Services
- Azure Synapse Analytics
- Azure Data Factory
- ETL / ETL processing
- Power BI (including DAX, Power BI embedded)
- Data Blob storage
- Data Lake storage
- Azure AI + Machine Learning services
- Azure Logic Apps
- Power BI Premium
- Maintain existing data infrastructure
- Build data systems and pipelines
- Evaluate business needs and objectives
- Analyze and organize raw data
- Interpret trends and patterns
- Conduct complex data analysis and report on results
- Prepare data for prescriptive and predictive modeling
- Build algorithms and prototypes
- Combine raw information from different sources
- Enhance data quality and reliability
- Identify opportunities for data acquisition
- Develop analytical tools and programs
- Collaborate with development and business team members on projects
- MS Azure certification(s) is an asset
- Azure AI + Machine Learning services
- Azure Logic Apps
- Power BI Premium
Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.
Company Size
10,001+
Company Stage
IPO
Headquarters
Pennsylvania
Founded
1907
Simplify's Take
What believers are saying
- OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
- EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
- FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.
What critics are saying
- Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
- McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
- Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.
What makes Cencora unique
- Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
- Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
- Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Parental Leave
Adoption Assistance
Infertility Coverage
Family Planning Benefits
Behavioral Health Solutions
Professional Development Budget
Training Programs
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.
Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.
Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.
Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.
Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.